{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:29:05Z","timestamp":1787020145318,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T00:00:00Z","timestamp":1691971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T00:00:00Z","timestamp":1691971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel was recommended as the secondary prevention of minor ischemic stroke or transient ischaemic attack (TIA). However, genetic polymorphisms of CYP2C19 had been identified as the major cause of poor responsiveness to clopidogrel. Ticagrelor, unlike clopidogrel, did not depend on metabolic activation, but it remained unclear whether ticagrelor was superior to clopidogrel in ischemic stroke. We performed a network meta-analysis to compare the efficacy and safety of ticagrelor, clopidogrel, and aspirin in the minor ischemic stroke and TIA populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Databases of Cochrane Library, ClinicalTrials.gov, and PubMed were searched up to June 19, 2023. Randomized controlled trials (RCTs) assessing antiplatelet drugs for minor stroke or TIA were included. Statistical processing was conducted by using multivariate meta-analysis routines of STATA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seven RCTs were included involving 41,745 participants. There was no significant difference between the two DAPTs in preventing stroke recurrence (OR, 1.16; 95% CI, 0.93-1.44), ischemic stroke recurrence (OR, 1.16; 95% CI, 0.93-1.45), and major hemorrhage (OR, 1.22; 95% CI, 0.62,2.39). Compared with aspirin alone, the two DAPT regimen reduced the risk of stroke recurrence (clopidogrel: OR, 0.69; 95% CI, 0.60-0.80, ticagrelor: OR, 0.66; 95% CI, 0.49-0.87) and ischemic stroke recurrence, but increased the incidence of major hemorrhage (clopidogrel: OR, 2.05; 95% CI, 1.22- 3.77; ticagrelor: OR, 2.55; 95% CI, 1.25-4.99). Despite being associated with a higher risk of any bleeding, ticagrelor did not impact the composite of vascular events or mortality. While ticagrelor and aspirin reduced the risk of ischemic stroke recurrence (OR, 0.77; 95% CI, 0.63- 0.92) without increasing the risk of major bleeding (OR 0.94; 95% CI 0.45\u20131.95) in the Asian population mainly Chinese.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>DAPT was superior to aspirin in stroke prevention, but little difference existed between the two DAPT regimens. Asian population mainly Chinese may benefit from DAPT with aspirin and ticagrelor. But further head-to-head RCTs are needed to validate the study results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-023-03356-7","type":"journal-article","created":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T05:02:11Z","timestamp":1691989331000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Ticagrelor plus aspirin in patients with minor ischemic stroke and transient ischemic attack: a network meta-analysis"],"prefix":"10.1186","volume":"23","author":[{"given":"Mingxia","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianru","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiankuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,14]]},"reference":[{"issue":"23","key":"3356_CR1","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1056\/NEJMoa1802712","volume":"378","author":"P Amarenco","year":"2018","unstructured":"Amarenco P, Lavall\u00e9e PC, Monteiro Tavares L, Labreuche J, Albers GW, Abboud H, Anticoli S, Audebert H, Bornstein NM, Caplan LR, Correia M, Donnan GA, Ferro JM, Gongora-Rivera F, Heide W, Hennerici MG, Kelly PJ, Kr\u00e1l M, Lin HF, Molina C, Park JM, Purroy F, Rothwell PM, Segura T, \u0160koloud\u00edk D, Steg PG, Touboul PJ, Uchiyama S, Vicaut \u00c9, Wang Y, Wong LKS. Five-year risk of stroke after tia or minor ischemic stroke. N Engl J Med. 2018;378(23):2182\u201390. https:\/\/doi.org\/10.1056\/NEJMoa1802712.","journal-title":"N Engl J Med"},{"issue":"3","key":"3356_CR2","doi-asserted-by":"publisher","first-page":"e0120105","DOI":"10.1371\/journal.pone.0120105","volume":"10","author":"C Zhang","year":"2015","unstructured":"Zhang C, Zhao X, Wang C, Liu L, Ding Y, Akbary F, Pu Y, Zou X, Du W, Jing J, Pan Y, Wong KS, Wang Y, Wang Y. Prediction factors of recurrent ischemic events in one year after minor stroke. PLoS ONE. 2015;10(3):e0120105. https:\/\/doi.org\/10.1371\/journal.pone.0120105.","journal-title":"PLoS ONE"},{"issue":"9","key":"3356_CR3","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1161\/strokeaha.107.513234","volume":"39","author":"SB Coutts","year":"2008","unstructured":"Coutts SB, Hill MD, Campos CR, Choi YB, Subramaniam S, Kosior JC, Demchuk AM. Recurrent events in transient ischemic attack and minor stroke: what events are happening and to which patients? Stroke. 2008;39(9):2461\u20136. https:\/\/doi.org\/10.1161\/strokeaha.107.513234.","journal-title":"Stroke"},{"issue":"1","key":"3356_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1001\/jamaneurol.2020.3627","volume":"78","author":"S Shahjouei","year":"2021","unstructured":"Shahjouei S, Sadighi A, Chaudhary D, Li J, Abedi V, Holland N, Phipps M, Zand R. A 5-decade analysis of incidence trends of ischemic stroke after transient ischemic attack: a systematic review and meta-analysis. JAMA Neurol. 2021;78(1):77\u201387. https:\/\/doi.org\/10.1001\/jamaneurol.2020.3627.","journal-title":"JAMA Neurol"},{"issue":"1","key":"3356_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1215340","volume":"369","author":"Y Wang","year":"2013","unstructured":"Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, Wang C, Li H, Meng X, Cui L, Jia J, Dong Q, Xu A, Zeng J, Li Y, Wang Z, Xia H, Johnston SC, Investigators C. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369(1):11\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1215340.","journal-title":"N Engl J Med"},{"issue":"3","key":"3356_CR6","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMoa1800410","volume":"379","author":"SC Johnston","year":"2018","unstructured":"Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, Kim AS, Lindblad AS, Palesch YY, Clinical Research Collaboration NETTN, the PI. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med. 2018;379(3):215\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1800410.","journal-title":"N Engl J Med"},{"issue":"11","key":"3356_CR7","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/s1474-4422(07)70250-8","volume":"6","author":"J Kennedy","year":"2007","unstructured":"Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. The Lancet Neurol. 2007;6(11):961\u20139. https:\/\/doi.org\/10.1016\/s1474-4422(07)70250-8.","journal-title":"The Lancet Neurol"},{"issue":"8","key":"3356_CR8","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1177\/0963689719851769","volume":"28","author":"H Lan","year":"2019","unstructured":"Lan H, Ying T, Xi-Hua S, Yi L. Anti-platelet therapy in mild cerebral infarction patients on the basis of CYP2C19 Metabolizer Status. Cell Trans. 2019;28(8):1039\u201344. https:\/\/doi.org\/10.1177\/0963689719851769.","journal-title":"Cell Trans"},{"issue":"3","key":"3356_CR9","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/ana.25535","volume":"86","author":"J Xu","year":"2019","unstructured":"Xu J, Wang A, Wangqin R, Mo J, Chen Z, Dai L, Meng X, Zhao X, Wang Y, Li H, Chen W, Xian Y, Wang Y, investigators C,. Efficacy of clopidogrel for stroke depends on CYP2C19 genotype and risk profile. Ann Neurol. 2019;86(3):419\u201326. https:\/\/doi.org\/10.1002\/ana.25535.","journal-title":"Ann Neurol"},{"issue":"1","key":"3356_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1161\/circulationaha.116.024913","volume":"135","author":"Y Pan","year":"2017","unstructured":"Pan Y, Chen W, Xu Y, Yi X, Han Y, Yang Q, Li X, Huang L, Johnston SC, Zhao X, Liu L, Zhang Q, Wang G, Wang Y, Wang Y. Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: A Systematic Review and Meta-Analysis. Circ. 2017;135(1):21\u201333. https:\/\/doi.org\/10.1161\/circulationaha.116.024913.","journal-title":"Circ"},{"issue":"2","key":"3356_CR11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/tpj.2015.70","volume":"16","author":"I Fricke-Galindo","year":"2016","unstructured":"Fricke-Galindo I, Cespedes-Garro C, Rodrigues-Soares F, Naranjo ME, Delgado A, de Andres F, Lopez-Lopez M, Penas-Lledo E, A LL,. Interethnic variation of CYP2C19 alleles, \u201cpredicted\u201d phenotypes and \u201cmeasured\u201d metabolic phenotypes across world populations. Pharmacogenomics J. 2016;16(2):113\u201323. https:\/\/doi.org\/10.1038\/tpj.2015.70.","journal-title":"Pharmacogenomics J"},{"issue":"11","key":"3356_CR12","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thors\u00e9n M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045\u201357. https:\/\/doi.org\/10.1056\/NEJMoa0904327.","journal-title":"N Engl J Med"},{"key":"3356_CR13","doi-asserted-by":"publisher","unstructured":"Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Jonasson J, Minematsu K, Molina CA, Wang Y, Wong KS, Committee SS, Investigators,. Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. N Engl J Med. 2016;375(1):35\u201343. https:\/\/doi.org\/10.1056\/NEJMoa1603060.","DOI":"10.1056\/NEJMoa1603060"},{"issue":"3","key":"3356_CR14","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1056\/NEJMoa1916870","volume":"383","author":"SC Johnston","year":"2020","unstructured":"Johnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James S, Knutsson M, Ladenvall P, Molina CA, Wang Y, Investigators T. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med. 2020;383(3):207\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1916870.","journal-title":"N Engl J Med"},{"key":"3356_CR15","doi-asserted-by":"publisher","first-page":"l2211","DOI":"10.1136\/bmj.l2211","volume":"365","author":"Y Wang","year":"2019","unstructured":"Wang Y, Chen W, Lin Y, Meng X, Chen G, Wang Z, Wu J, Wang D, Li J, Cao Y, Xu Y, Zhang G, Li X, Pan Y, Li H, Zhao X, Liu L, Lin J, Dong K, Jing J, Johnston SC, Wang D, Wang Y, Group PPS. Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial. BMJ. 2019;365:l2211. https:\/\/doi.org\/10.1136\/bmj.l2211.","journal-title":"BMJ"},{"issue":"27","key":"3356_CR16","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1056\/NEJMoa2111749","volume":"385","author":"Y Wang","year":"2021","unstructured":"Wang Y, Meng X, Wang A, Xie X, Pan Y, Johnston SC, Li H, Bath PM, Dong Q, Xu A, Jing J, Lin J, Niu S, Wang Y, Zhao X, Li Z, Jiang Y, Li W, Liu L, Xu J, Chang L, Wang L, Zhuang X, Zhao J, Feng Y, Man H, Li G, Wang B, Investigators C. Ticagrelor versus clopidogrel in cyp2c19 loss-of-function carriers with stroke or TIA. N Engl J Med. 2021;385(27):2520\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2111749.","journal-title":"N Engl J Med"},{"issue":"2","key":"3356_CR17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1001\/jamaneurol.2021.4514","volume":"79","author":"R Lun","year":"2022","unstructured":"Lun R, Dhaliwal S, Zitikyte G, Roy DC, Hutton B, Dowlatshahi D. Comparison of ticagrelor vs clopidogrel in addition to aspirin in patients with minor ischemic stroke and transient ischemic attack: a network meta-analysis. JAMA Neurol. 2022;79(2):141\u20138. https:\/\/doi.org\/10.1001\/jamaneurol.2021.4514.","journal-title":"JAMA Neurol"},{"key":"3356_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/svn-2021-001423","author":"X Chen","year":"2022","unstructured":"Chen X, Xu J, Chen S, Dong Q, Dong Y. Dual antiplatelet therapy with ticagrelor may increase the risk of all bleeding events in patients with minor strokes or high risk TIAs: a meta-analysis. Stroke Vasc Neurol. 2022. https:\/\/doi.org\/10.1136\/svn-2021-001423.","journal-title":"Stroke Vasc Neurol"},{"issue":"11","key":"3356_CR19","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/m14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catal\u00e1-L\u00f3pez F, G\u00f8tzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384. https:\/\/doi.org\/10.7326\/m14-2385.","journal-title":"Ann Intern Med"},{"key":"3356_CR20","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hernan MA, Hopewell S, Hrobjartsson A, Junqueira DR, Juni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"3356_CR21","doi-asserted-by":"publisher","first-page":"m3907","DOI":"10.1136\/bmj.m3907","volume":"371","author":"R Brignardello-Petersen","year":"2020","unstructured":"Brignardello-Petersen R, Izcovich A, Rochwerg B, Florez ID, Hazlewood G, Alhazanni W, Yepes-Nunez J, Santesso N, Guyatt GH, Schunemann HJ, group Gw. GRADE approach to drawing conclusions from a network meta-analysis using a partially contextualised framework. BMJ. 2020;371:m3907. https:\/\/doi.org\/10.1136\/bmj.m3907.","journal-title":"BMJ"},{"issue":"4","key":"3356_CR22","doi-asserted-by":"publisher","first-page":"e1003082","DOI":"10.1371\/journal.pmed.1003082","volume":"17","author":"A Nikolakopoulou","year":"2020","unstructured":"Nikolakopoulou A, Higgins JPT, Papakonstantinou T, Chaimani A, Del Giovane C, Egger M, Salanti G. CINeMA: An approach for assessing confidence in the results of a network meta-analysis. PLoS Med. 2020;17(4):e1003082. https:\/\/doi.org\/10.1371\/journal.pmed.1003082.","journal-title":"PLoS Med"},{"issue":"19","key":"3356_CR23","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1016\/j.jacc.2007.07.058","volume":"50","author":"RF Storey","year":"2007","unstructured":"Storey RF, Husted S, Harrington RA, Heptinstall S, Wilcox RG, Peters G, Wickens M, Emanuelsson H, Gurbel P, Grande P, Cannon CP. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol. 2007;50(19):1852\u20136. https:\/\/doi.org\/10.1016\/j.jacc.2007.07.058.","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"3356_CR24","doi-asserted-by":"publisher","first-page":"20085","DOI":"10.18632\/aging.103452","volume":"12","author":"Y Yang","year":"2020","unstructured":"Yang Y, Chen W, Pan Y, Yan H, Meng X, Liu L, Wang Y, Wang Y. Effect of ticagrelor versus clopidogrel on platelet reactivity measured by thrombelastography in patients with minor stroke or TIA. Aging. 2020;12(20):20085\u201394. https:\/\/doi.org\/10.18632\/aging.103452.","journal-title":"Aging"},{"issue":"1","key":"3356_CR25","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1001\/jama.2016.8662","volume":"316","author":"Y Wang","year":"2016","unstructured":"Wang Y, Zhao X, Lin J, Li H, Johnston SC, Lin Y, Pan Y, Liu L, Wang D, Wang C, Meng X, Xu J, Wang Y, investigators C,. Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack. JAMA. 2016;316(1):70\u20138. https:\/\/doi.org\/10.1001\/jama.2016.8662.","journal-title":"JAMA"},{"issue":"16","key":"3356_CR26","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1056\/NEJMoa1412981","volume":"374","author":"P Amarenco","year":"2016","unstructured":"Amarenco P, Lavallee PC, Labreuche J, Albers GW, Bornstein NM, Canhao P, Caplan LR, Donnan GA, Ferro JM, Hennerici MG, Molina C, Rothwell PM, Sissani L, Skoloudik D, Steg PG, Touboul PJ, Uchiyama S, Vicaut E, Wong LK, Investigators TIo,. One-year risk of stroke after transient ischemic attack or minor stroke. N Engl J Med. 2016;374(16):1533\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1412981.","journal-title":"N Engl J Med"},{"issue":"12","key":"3356_CR27","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1161\/STROKEAHA.120.032239","volume":"51","author":"P Amarenco","year":"2020","unstructured":"Amarenco P, Denison H, Evans SR, Himmelmann A, James S, Knutsson M, Ladenvall P, Molina CA, Wang Y, Johnston SC, Committee TS, Investigators*. Ticagrelor added to aspirin in acute nonsevere ischemic stroke or transient ischemic attack of atherosclerotic origin. stroke. 2020;51(12):3504\u201313. https:\/\/doi.org\/10.1161\/STROKEAHA.120.032239.","journal-title":"Stroke"},{"issue":"12","key":"3356_CR28","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1161\/STROKEAHA.112.668988","volume":"43","author":"JJ DiNicolantonio","year":"2012","unstructured":"DiNicolantonio JJ, Serebruany VL. Comparing ticagrelor versus clopidogrel in patients with a history of cerebrovascular disease: a net clinical harm? Stroke. 2012;43(12):3409\u201310. https:\/\/doi.org\/10.1161\/STROKEAHA.112.668988.","journal-title":"Stroke"},{"issue":"23","key":"3356_CR29","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1161\/CIRCULATIONAHA.111.082727","volume":"125","author":"SK James","year":"2012","unstructured":"James SK, Storey RF, Khurmi NS, Husted S, Keltai M, Mahaffey KW, Maya J, Morais J, Lopes RD, Nicolau JC, Pais P, Raev D, Lopez-Sendon JL, Stevens SR, Becker RC. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. Circ. 2012;125(23):2914\u201321. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.082727.","journal-title":"Circ"},{"issue":"1","key":"3356_CR30","doi-asserted-by":"publisher","first-page":"7383","DOI":"10.1038\/s41598-021-86824-9","volume":"11","author":"Z Cai","year":"2021","unstructured":"Cai Z, Cai WR, Wang H, Yu Z, Gao F, Liu Y, Kang Y, Wu Z. Cost-effectiveness of CYP2C19 genotyping to guide antiplatelet therapy for acute minor stroke and high-risk transient ischemic attack. Sci Rep. 2021;11(1):7383. https:\/\/doi.org\/10.1038\/s41598-021-86824-9.","journal-title":"Sci Rep"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-023-03356-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-023-03356-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-023-03356-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T14:19:16Z","timestamp":1700489956000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-023-03356-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,14]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3356"],"URL":"https:\/\/doi.org\/10.1186\/s12883-023-03356-7","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,14]]},"assertion":[{"value":"21 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study did not require any ethics committee approval because of its non-experimental design.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests..","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"303"}}